Project Grant R21CA258013

Award Date 6/3/21
Completion Date 5/31/25
Dollars Obligated $935K
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Mountain View, CA 94043, USA
Similar Awards
The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This $3.7 million project grant from the National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering will fund research at Arizona State University to develop RNA stabilizing elements that improve coronavirus diagnostics. Specifically, the university will model the role of 5' secondary structures in modulating mRNA stability, optimize sensing RNAs to detect SARS-CoV-2, and use degradable trans-acting RNAs to enhance sample and amplified RNA stability....
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $980,779 to the University of Cincinnati to develop a deployable and adaptable plasmonic sensing platform for infectious disease surveillance. The key objectives are to create a sensing platform capable of detecting multiple genetic biomarkers in liquid...
This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award provides $274,362 to RT Microdx Inc., a small minority-owned business, to develop a novel molecular diagnostic platform for at-home detection of respiratory diseases like strep throat. The platform leverages isothermal amplification and pH-sensitive polymers to enable rapid, accurate, and user-friendly testing without the need for an expensive tabletop device. The anticipated...
This $329,737 Project Grant awarded on September 12, 2023 by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), is supporting the development of a rapid, easy-to-use diagnostic platform for the point-of-care detection of high-risk HPV in saliva. The grantee, Innotech Precision Medicine, Inc., is working to create an innovative electrochemical biosensor that combines CRISPR-Cas12 technology with their...
This $415,830 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop an integrated nanoplasmonic sensing platform termed "Nano-CRISPR" for longitudinal tumor monitoring in ovarian cancer patients. The key products and services to be delivered include: Incorporation of single extracellular vesicle (EV) capture and analysis using plasmonic nanodisk arrays, CRISPR/Cas13a sensors for lysis-free,...
This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $1,077,369 to Captis Diagnostics Inc., a self-certified small disadvantaged business, to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for rapid, efficient isolation of extracellular vesicles (EVs) from non-invasive bodily fluids such as blood plasma, serum, urine, and saliva. The project aims to optimize the LNP technology and deliver four EV isolation kits as...
This $265,347 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development and initial validation of a point-of-care device by Functional Fluidics Inc. to assess red blood cell sickling in patients with sickle cell disease. The goal is to create a simple, stand-alone, and potentially CLIA-waived diagnostic system that can be used to monitor patient condition and treatment response, especially for drugs affecting...

DEVICE FOR PRESERVATION OF CELL FREE RNA IN SALIVA - ABSTRACT EARLY DETECTION IS CRITICAL TO CANCER MORTALITY REDUCTIONS, AND YET THE BREAST IMAGING CLINIC VISITS REQUIRED FOR THESE LIFE-SAVING EARLY DETECTION PROGRAMS ARE INACCESSIBLE TO DISADVANTAGED, REMOTE, OR QUARANTINED POPULATIONS WITH LIMITED MEDICAL FACILITY ACCESS. IN FACT, BREAST CANCER SURVEILLANCE PROGRAMS THIS YEAR HAVE STALLED BY AS MUCH AS 90% VERSUS THEIR PRE-PANDEMIC RATES, RESULTING IN RISKY DELAYS IN NEW CANCER DIAGNOSIS [1]. A SALIVA-BASED TEST FOR EARLY DETECTION COULD TRANSFORM TODAY'S SCREENING PARADIGMS. A PROMISING BIOFLUID FOR DISEASE DETECTION, SALIVA CAN BE SELF-SAMPLED NON-INVASIVELY, WITHOUT TRAINED TECHNICIANS. SALIVA IS IDEAL FOR AT-HOME AND OTHER NON-CLINICAL SITE COLLECTION; IT CONTAINS A VARIETY OF ANALYTES INCLUDING EXOSOMES, RNA, DNA, PROTEINS, METABOLITES, VIRUSES AND ORAL MICROFLORA, AND IS A POWERFUL WINDOW ON HEALTH AND DISEASE. RECENTLY, SALIVA SAMPLES HAVE SHOWN BETTER CLINICAL UTILITY VS. NASAL SWABS FOR DETECTING COVID-19 [2]. MOUNTING EVIDENCE EXISTS FOR ORAL MICROBIOME LINKS TO SYSTEMIC DISEASE [3], AND SALIVARY BIOMARKERS DIAGNOSE COMPLEX TRAITS SUCH AS PEDIATRIC MEDICAL CONDITIONS, TRAUMATIC BRAIN INJURY, AUTISM, AND CANCER [4-7]. A COMMERCIAL SALIVA-BASED TEST FOR AUTISM IS BASED ON 32 HUMAN AND MICROBIAL RNA MARKERS [8]. IN MANY COMPLEX TRAIT STUDIES, SALIVA IS FROZEN AS CELL-FREE SUPERNATANT. THE MOST PREVALENT SALIVA COLLECTION AND PRESERVATION DEVICES, ALTHOUGH EASY-TO-USE, PRECLUDE EFFECTIVE CELL-FREE RNA AND EXOSOME ANALYSIS, SINCE SALIVA SAMPLES ARE TREATED WITH LYSIS REAGENTS RESULTING IN MIXED POPULATIONS OF CELLULAR AND NON-CELLULAR RNAS, INCREASING NOISE AND DAMAGING PERFORMANCE CHARACTERISTICS. SALIVA COLLECTION DEVICES THAT INSTEAD USE MEMBRANES TO SEPARATE CELLS SUFFER FROM INEFFICIENT RECOVERY OF CRITICAL ANALYTES, EITHER BECAUSE THEY LACK APPROPRIATE PRESERVATIVES OR BECAUSE THEY ADSORB AND THEREFORE LOSE, A SUBSTANTIAL ANALYTE FRACTION. TO ENABLE WIDESPREAD USE FOR DISEASE DETECTION, NEW STANDARDIZED METHODS ARE NEEDED TO PRESERVE CELL-FREE SALIVA AND RETAIN THE INTEGRITY OF ITS KEY CONSTITUENTS FOR STABLE TRANSPORT AND DOWNSTREAM ANALYSIS. THIS PROJECT EXTENDS OUR PAST SBIR GRANT WORK AND OUR OWN INTERNAL RESEARCH, TO DEVELOP AN EASY-TO-USE SALIVA COLLECTION AND PRESERVATION DEVICE TO STABILIZE CFRNA AND OTHER ANALYTES, ENABLING US AND OTHERS TO EFFICIENTLY COLLECT HIGH-QUALITY CLINICAL SALIVA SAMPLES. USING RT-QPCR ASSAYS AND RNA ISOTYPE PROFILES, WE WILL CHARACTERIZE SALIVARY CFRNA INTEGRITY AND STABILITY OVER TIMELINES SUFFICIENT FOR REMOTE COLLECTION AND TRANSPORT. ARMED WITH WELL-CHARACTERIZED RNA DECAY PROFILES, WE PROPOSE AN ITERATIVE DESIGN-OF-EXPERIMENT APPROACH TO PROTOTYPE A VERSATILE DEVICE TO COLLECT AND PRESERVE SALIVA AT ROOM TEMPERATURE (RT), STABILIZING RNA WHILE ALSO PREVENTING CELL LYSIS AND BACTERIAL GROWTH. OUR DEVICE PERFORMANCE VALIDATION WILL USE PROSPECTIVELY COLLECTED AND PRESERVED SALIVA FROM >50 WOMEN TO DEMONSTRATE STABILITY FOR UP 72 HOURS AT AMBIENT CONDITIONS. THIS DEVICE WILL STANDARDIZE METHODS FOR COLLECTION, STABILITY, AND TRANSPORT OF SALIVA, KEY TO DRIVING VIRTUALIZED SAMPLE COLLECTION AND HEALTHCARE IN CANCER, VIRAL, AND OTHER DIAGNOSTICS, INCREASINGLY CRITICAL TO A POST-PANDEMIC WORLD.

Posted 6/3/21, 12:00 AM